Parkinson's: Asthma drugs may cut risk by a third

A study including cell cultures, experiments in mice, and an overview of more than 100 million prescriptions shows asthma drugs lower Parkinson's risk.
Source: Parkinson's Disease News From Medical News Today - Category: Neurology Tags: Parkinson's Disease Source Type: news

Related Links:

Abstract Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). 5-LOX is activated by enzyme 5-Lipoxygenase-activating protein (FLAP), which further lead to production of cysLTs i.e. leukotriene C4 (LTC4), leukotriene D4 (LTD4) and leukotriene E4 (LTE4). CysLTs then produce their potent inflammatory actions by activating CysLT1 and CysLT2 receptors. Inhibitors of cysLTs are indicated in asthma, allergic rhinitis and other inflammatory disorders. Earlier studies have associated cysLTs and ...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
As DNA is the new oil (or bacon?), and its amount continues to increase exponentially, technical, ethical, legal as well as security and privacy challenges arise by the dozens. The Medical Futurist believes now is the time for concerted, community-wide planning for the genomic data challenges of the next decade. The amount of genomic data is soaring – and the challenges growing Imagine genes as sentences and genomes as entire books consisting of tens of thousands of chains of words. Interpreting the whole book for the first time by completing the Human Genome Project took more than 15 years. It’s fascinating ho...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Genomics Healthcare Policy Medical Professionals Patients Policy Makers big data bioethics DNA genetic genetics genome sequencing genomic data population genomics technology Source Type: blogs
Abstract Parkinson's disease (PD) is a neurodegenerative and debilitating disease that affects 1% of elderly population. Patient's motor disability results in an extreme difficulty to deal with daily activities. Conventional treatment is limited to dopamine replacement therapy, which fails to delay disease's progression and is often associated with a number of adverse reactions. Recent progress in understanding the mechanisms involved in PD has revealed new molecular targets for therapeutic approaches. Among them, caffeine and xanthine derivatives are promising drug candidates, because of the possible symptomatic ...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
This case was written by one of ourgreat Hennepin 2nd year residents, Aaron Robinson, with lots of comments and edits by Smith.Thanks to Dr. Smith and Dr. Travis Olives for being part of this case. A 12 year old girl with a history of mild intermittent asthma presented to the emergency department with worsening shortness of breath over the past couple of days. She is up to date on her vaccinations and has no PMHx besides asthma and a noncontributory family history. She does not identify any specific triggers for her asthma. Initial screen in triage revealed normal vitals signs and a normal temperature. Upon interviewi...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
Johnson &Johnson (NYSE:JNJ) opened its latest life science incubator in New York City, the healthcare giant said today. The 30,000-square-foot JLabs @ NYC is a collaboration between Johnson &Johnson Innovation, New York State and the New York Genome Center. Sited at the genome center in SoHo, the incubator is home to 26 startups and has room for four more, New Brunswick, N.J.-based J&J said. “Johnson &Johnson has deep entrepreneurial roots in New York and we are pleased to see our unique JLabs model applied in this rich ecosystem to foster the creation of new healthcare innovations that have the pote...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Research & Development johnsonandjohnson Source Type: news
AbstractPurpose of ReviewThe sense of smell is today one of the focuses of interest in aging and neurodegenerative disease research. In several neurodegenerative diseases, such as Parkinson ’s disease and Alzheimer’s disease, the olfactory dysfunction is one of the initial symptoms appearing years before motor symptoms and cognitive decline, being considered a clinical marker of these diseases’ early stages and a marker of disease progression and cognitive decline. Overall and un der the umbrella of precision medicine, attention to olfactory function may help to improve chances of success for neuroprotect...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Researchers from the University of Washington found people who take  corticosteroids, which are commonly prescribed for psoriasis and ulcerative colitis, are 20 percent less at risk of suffering tremors.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Inflammation is one of the major causes of the development of various diseases like arthritis, cancer, cardiovascular disease, diabetes, obesity, osteoporosis, inflammatory bowel disease, asthma, and even central nervous system (CNS)-related diseases such as depression and Parkinson's disease [1]. Reports in the literature suggest that almost 90% of synthetic antiinflammatory drugs produce drug-related toxicities, iatrogenic reactions, and adverse effects compromising the treatment process [2,3].
Source: Nutrition - Category: Nutrition Authors: Tags: Basic nutritional investigation Source Type: research
Authors: Yeh JJ, Wei YF, Lin CL, Hsu WH Abstract Background: To evaluate the association of asthma-chronic obstructive pulmonary disease syndrome (ACOS) with neurodegenerative diseases (stroke, Parkinson's disease and dementia) and the role of the steroids in the neurodegenerative diseases among the ACOS cohort. Materials and Methods: Comparison of the ACOS cohort (N = 10,260) with the non-ACOS cohort (n = 20,513) based on the patients aged ≧40 years in the National Health Insurance Research Database from January 1, 2000 to December 31, 2010. These patients follow up to diagnosis of neurodegenerative diseases...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
No abstract available
Source: Neurology Today - Category: Neurology Tags: Features Source Type: research
More News: Asthma | Parkinson's Disease | Study